Antiresorptive and anti-angiogenic drug therapy in the pediatric population with reference to medication-related osteonecrosis of the jaw.

Autor: McLaurin WS; Division of Oral and Maxillofacial Surgery, University of Cincinnati College of Medicine, Cincinnati, OH, USA., Francisco BJ; Division of Pediatric Hematology-Oncology, Icahn School of Medicine at Mount Sinai, New York City, NY, USA., Hooker KJ; Department of Chemistry and Chemical Biology, Rensselaer Polytechnic Institute, Troy, NY, USA., Sheshashayee N; Department of Environmental and Public Health Sciences, Division of Biostatistics, University of Cincinnati College of Medicine, Cincinnati, OH, USA., Khan MTF; Department of Mathematics and Statistics, Cleveland State University, Cleveland, OH, USA., Triana RR; Division of Oral and Maxillofacial Surgery, University of Cincinnati College of Medicine, Cincinnati, OH, USA., Rao MB; Department of Environmental and Public Health Sciences, Division of Biostatistics, University of Cincinnati College of Medicine, Cincinnati, OH, USA., Pressey JG; Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA., Krishnan DG; Division of Oral and Maxillofacial Surgery, University of Cincinnati College of Medicine, Cincinnati, OH, USA. Electronic address: deepak.krishnan@uc.edu.
Jazyk: angličtina
Zdroj: International journal of oral and maxillofacial surgery [Int J Oral Maxillofac Surg] 2024 Jun; Vol. 53 (6), pp. 496-502. Date of Electronic Publication: 2023 Nov 28.
DOI: 10.1016/j.ijom.2023.11.001
Abstrakt: The objective of this study was to identify the prevalence of osteonecrosis of the jaw in a pediatric population with systemic therapeutic exposure to an antiresorptive, anti-angiogenic, and/or immunomodulating drug (ARAID), and in particular in the subgroup of patients who had undergone invasive dental treatment. This was a retrospective cohort study performed at a single center. The investigation included pediatric patients who had undergone systemic therapy with ARAIDs and who began receiving ARAID therapy at ≤16 years of age. The study included 482 patients who received ARAIDs between January 2011 and January 2021. The most common medication class was bisphosphonates (45.0%), followed by mTOR inhibitors (30.1%) and anti-angiogenics (17.8%). No diagnosis of osteonecrosis of the jaw was observed. From this population, 26 patients were noted to have undergone invasive dental treatment. The duration from treatment to the invasive procedure ranged from 0 to 5.9 years. Medication-related osteonecrosis of the jaw is extremely rare among the pediatric population - much less common when compared to the adult population. Prospective cohort studies and continued evaluation will help determine the incidence and prevalence of medication-related osteonecrosis of the jaw in pediatric patients.
(Copyright © 2023 International Association of Oral and Maxillofacial Surgeons. Published by Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: